ICML 2019 | Single agent ibrutinib produces long-term disease control in Waldenström’s: the pivotal trial

Steven Treon

Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, presents the final report of the pivotal trial of ibrutinib monotherapy for previously treated Waldenström’s macroglobulinemia (NCT01614821). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video